FI940642A0 - Imidatsolyyli-alkeenihapot - Google Patents

Imidatsolyyli-alkeenihapot

Info

Publication number
FI940642A0
FI940642A0 FI940642A FI940642A FI940642A0 FI 940642 A0 FI940642 A0 FI 940642A0 FI 940642 A FI940642 A FI 940642A FI 940642 A FI940642 A FI 940642A FI 940642 A0 FI940642 A0 FI 940642A0
Authority
FI
Finland
Prior art keywords
alkenoic
imidazolyl
Prior art date
Application number
FI940642A
Other languages
English (en)
Swedish (sv)
Other versions
FI940642A (fi
FI114796B (fi
Inventor
Richard Mcculloch Keenan
Joseph Weinstock
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of FI940642A publication Critical patent/FI940642A/fi
Publication of FI940642A0 publication Critical patent/FI940642A0/fi
Application granted granted Critical
Publication of FI114796B publication Critical patent/FI114796B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI940642A 1991-08-14 1994-02-11 Menetelmä farmaseuttisesti aktiivisen (E)-3-[2-n-butyyli-1-{(4-karboksifenyyli)metyyli}-1H-imidatsol-5-yyli]-2-(2-tienyyli)metyyli-2-propeenihappometaanisulfonaatin valmistamiseksi FI114796B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/746,262 US5185351A (en) 1989-06-14 1991-08-14 Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US74626291 1991-08-14
PCT/US1992/006734 WO1993003722A1 (en) 1991-08-14 1992-08-12 Imidazolyl-alkenoic acids
US9206734 1992-08-12

Publications (3)

Publication Number Publication Date
FI940642A FI940642A (fi) 1994-02-11
FI940642A0 true FI940642A0 (fi) 1994-02-11
FI114796B FI114796B (fi) 2004-12-31

Family

ID=25000103

Family Applications (1)

Application Number Title Priority Date Filing Date
FI940642A FI114796B (fi) 1991-08-14 1994-02-11 Menetelmä farmaseuttisesti aktiivisen (E)-3-[2-n-butyyli-1-{(4-karboksifenyyli)metyyli}-1H-imidatsol-5-yyli]-2-(2-tienyyli)metyyli-2-propeenihappometaanisulfonaatin valmistamiseksi

Country Status (33)

Country Link
US (1) US5185351A (fi)
EP (1) EP0641203B1 (fi)
JP (1) JPH07500579A (fi)
CN (1) CN1036396C (fi)
AP (3) AP525A (fi)
AT (1) ATE226073T1 (fi)
AU (1) AU667824B2 (fi)
BG (1) BG61593B1 (fi)
BR (1) BR9206443A (fi)
CA (1) CA2115170C (fi)
CZ (1) CZ281635B6 (fi)
DE (1) DE69232817T2 (fi)
DK (1) DK0641203T3 (fi)
ES (1) ES2185617T3 (fi)
FI (1) FI114796B (fi)
HK (1) HK1012246A1 (fi)
HU (1) HU225048B1 (fi)
IL (1) IL102813A (fi)
MA (1) MA22626A1 (fi)
MX (1) MX9204737A (fi)
MY (1) MY110205A (fi)
NO (1) NO305172B1 (fi)
NZ (1) NZ243966A (fi)
OA (1) OA09884A (fi)
PL (1) PL177234B1 (fi)
PT (1) PT100779B (fi)
RO (1) RO113643B1 (fi)
RU (1) RU2124513C1 (fi)
SK (1) SK281252B6 (fi)
TW (1) TW234690B (fi)
UA (1) UA40587C2 (fi)
WO (1) WO1993003722A1 (fi)
ZA (1) ZA926133B (fi)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5418250A (en) * 1989-06-14 1995-05-23 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
GB9027200D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6034114A (en) * 1990-12-14 2000-03-07 Smithkline Beecham Plc Medicament
EP0563238B1 (en) * 1990-12-14 2002-05-22 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
US6028091A (en) * 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
US5447949A (en) * 1991-05-15 1995-09-05 Smithkline Beecham Corporation N-(heteroaryl) imidazolyl-alkenoic acids having angiotension II receptor antagonist activity
US20030166700A1 (en) * 1991-12-12 2003-09-04 Smithkline Beecham P.L.C. Medicament
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
DE4206043A1 (de) * 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl-substituierte imidazole
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US5395847A (en) * 1993-12-02 1995-03-07 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
PL185858B1 (pl) * 1994-05-20 2003-08-29 Smithkline Beecham Corp Związek addycyjny kwasu 4-[(2-n-butylo-5-formylo-1Związek addycyjny kwasu 4-[(2-n-butylo-5-formylo-1H-imidazol-1-ilo)metylo]benzoesowego z wodorosiarcH-imidazol-1-ilo)metylo]benzoesowego z wodorosiarczynem i sposób jego wytwarzaniazynem i sposób jego wytwarzania
MX9700041A (es) * 1994-06-29 1997-04-30 Smithkline Beecham Corp Antagonistas de receptor de vitronectina.
US6613789B2 (en) 1994-07-28 2003-09-02 G. D. Searle & Co. Heterocyclo-substituted imidazoles for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
UA49880C2 (uk) * 1996-03-29 2002-10-15 Смітклайн Бічам Корпорейшн Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі
US6420412B2 (en) 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
AR011126A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano y compuestos intermediarios.
AR011125A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano
ZA984421B (en) * 1997-05-27 1998-11-27 Smithkline Beecham Corp Method of treating isolated systolic hypertension
US20030045561A1 (en) * 2001-02-06 2003-03-06 Smithkline Beecham Corporation Method of treating isolated systolic hypertension
DE69807695T2 (de) * 1997-06-27 2003-07-31 Smithkline Beecham Corp Eprosartan-monohydrate
US6630498B2 (en) 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
ATE341325T1 (de) * 1997-08-06 2006-10-15 Smithkline Beecham Corp Eprosartan arginyl-ladungsneutralisationskomplex und verfahren zu dessen herstellung und verabreichung
KR100597922B1 (ko) * 1997-11-17 2006-07-10 스미스클라인 비참 코포레이션 고용량 약물 로딩 속효성 및 변형 방출형 경구 투여용제형 및 그의 제조 방법
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
HUP0103000A3 (en) * 1998-07-20 2002-08-28 Smithkline Beecham Corp Bioenhanced formulations comprising eprosartan in oral solid dosage form and process for their preparation
DK1100789T3 (da) 1998-07-24 2005-05-23 Bayer Cropscience Ag Substituerede benzoylcyclohexandioner
DE19920791A1 (de) * 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19946853A1 (de) 1999-09-30 2001-04-05 Bayer Ag Substituierte Arylketone
DE10004084A1 (de) * 2000-01-31 2001-08-02 Bayer Ag Substituierte Imid-Derivate
DE10221121A1 (de) * 2002-05-13 2003-12-04 Bayer Cropscience Ag N'-Cyano-N-methyl-imidamid-Derivate
AU2003250483A1 (en) 2002-08-19 2004-03-11 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
CA2753318A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
WO2005039639A2 (en) * 2003-10-10 2005-05-06 Solvay Pharmaceuticals Gmbh Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
KR20070084455A (ko) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 지질혈증 치료용 ｈｍｇ ｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
KR20080074128A (ko) * 2005-12-06 2008-08-12 산텐 세이야꾸 가부시키가이샤 각결막 장애 치료제
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
TW200811101A (en) * 2006-07-14 2008-03-01 Ranbaxy Lab Ltd Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
US20080014263A1 (en) * 2006-07-17 2008-01-17 Glenmark Pharmaceuticals Limited Amorphous eprosartan mesylate and process for the preparation thereof
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US20100137613A1 (en) * 2006-12-27 2010-06-03 Hetero Drugs Limited Process for eprosartan
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009013760A2 (en) * 2007-07-25 2009-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
EP2295430A3 (en) * 2007-07-25 2011-08-03 Hetero Drugs Limited Crystalline solid of eprosartan acetate
CN101896457A (zh) * 2007-10-22 2010-11-24 幽兰研究实验室有限公司 组蛋白脱乙酰基酶抑制剂
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101215284B (zh) * 2007-12-31 2010-10-13 浙江华海药业股份有限公司 一种改进的依普罗沙坦的制备方法
US20110054186A1 (en) * 2008-03-31 2011-03-03 Hetero Research Foundation Process for eprosartan intermediate
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CN101333216A (zh) * 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
WO2011004384A2 (en) 2009-06-05 2011-01-13 Glochem Industries Limited Process for the preparation of eprosartan
WO2011051975A1 (en) 2009-10-30 2011-05-05 Matrix Laboratories Ltd An improved process for the preparation of pure eprosartanand its pharmaceutical acceptable salts
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2012303683B2 (en) 2011-08-26 2016-09-08 Wockhardt Limited Methods for treating cardiovascular disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015012205A1 (ja) 2013-07-23 2015-01-29 第一三共株式会社 高血圧症の予防又は治療のための医薬
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP6934859B2 (ja) 2016-03-24 2021-09-15 第一三共株式会社 腎疾患の治療のための医薬
CN117542473A (zh) 2018-06-14 2024-02-09 阿斯利康(英国)有限公司 用血管紧张素ii受体阻滞剂医药组合物治疗高血压的方法
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS58157768A (ja) * 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
EP0955294B1 (en) * 1989-06-14 2003-09-24 Smithkline Beecham Corporation Imidazolyl-alkenoic acid
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
GB9027197D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027198D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
JP3398379B2 (ja) * 1990-12-14 2003-04-21 スミスクライン・ビーチャム・コーポレイション アンジオテンシンｉｉ受容体遮断組成物
GB9027209D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027199D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
EP0563238B1 (en) * 1990-12-14 2002-05-22 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027201D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027200D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027212D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments

Also Published As

Publication number Publication date
CZ281635B6 (cs) 1996-11-13
CN1070645A (zh) 1993-04-07
CN1036396C (zh) 1997-11-12
EP0641203A1 (en) 1995-03-08
ES2185617T3 (es) 2003-05-01
AP9200416A0 (en) 1992-10-31
PT100779B (pt) 1999-07-30
HU9400413D0 (en) 1994-05-30
CZ31194A3 (en) 1994-12-15
JPH07500579A (ja) 1995-01-19
FI940642A (fi) 1994-02-11
TW234690B (fi) 1994-11-21
ZA926133B (en) 1993-03-31
FI114796B (fi) 2004-12-31
NO305172B1 (no) 1999-04-12
AU667824B2 (en) 1996-04-18
DE69232817D1 (de) 2002-11-21
PL177234B1 (pl) 1999-10-29
SK281252B6 (sk) 2001-01-18
AP9500741A0 (en) 1995-07-31
ATE226073T1 (de) 2002-11-15
AP9500742A0 (en) 1995-07-31
MY110205A (en) 1998-02-28
EP0641203B1 (en) 2002-10-16
US5185351A (en) 1993-02-09
OA09884A (en) 1994-09-15
UA40587C2 (uk) 2001-08-15
AP527A (en) 1996-09-06
IL102813A0 (en) 1993-01-31
SK13594A3 (en) 1994-08-10
MX9204737A (es) 1994-02-28
CA2115170A1 (en) 1993-03-04
DK0641203T3 (da) 2003-02-17
BG98454A (bg) 1995-02-28
DE69232817T2 (de) 2003-06-18
BG61593B1 (bg) 1998-01-30
HU225048B1 (en) 2006-05-29
HK1012246A1 (en) 1999-07-30
AP525A (en) 1996-09-06
WO1993003722A1 (en) 1993-03-04
NZ243966A (en) 1996-08-27
EP0641203A4 (en) 1994-06-09
PT100779A (pt) 1993-09-30
CA2115170C (en) 2004-05-25
AU2475692A (en) 1993-03-16
HUT70157A (en) 1995-09-28
BR9206443A (pt) 1994-09-27
IL102813A (en) 1999-07-14
RU2124513C1 (ru) 1999-01-10
RO113643B1 (ro) 1998-09-30
NO940476D0 (no) 1994-02-11
MA22626A1 (fr) 1993-04-01
NO940476L (no) 1994-04-11
AP526A (en) 1996-09-06

Similar Documents

Publication Publication Date Title
DE69133396D1 (de) Warenauszahlsystem
FI940642A0 (fi) Imidatsolyyli-alkeenihapot
DE59206583D1 (de) Windsichter
ATE137279T1 (de) Stoffauflauf
DE59209950D1 (de) Flaschendispenser
ATA131391A (de) Reibring
NO924252D0 (no) Magnetoencefalograf
BR9204511A (pt) Recolhedor-enrolador
DE59208716D1 (de) Lymphoides cd30-antigen
DE59207013D1 (de) Sportschuh
FI915023A (fi) Vattenloesliga kolofoniumpolyamidhartser
ATA39792A (de) Maehwerk
FI923386A (fi) Foerbaettrad braenslestavsenhet foer en kokarreaktor
ATA170491A (de) Mauerstein
DE69126968T2 (de) Tamburin
ATA9892A (de) Formstein
ATA67791A (de) Rollski
NO921717D0 (no) Polyvinylkloridblandinger
BR9201945A (pt) Filatorio
FI88195C (fi) Foenster
CA68725S (fr) Mobilier-jeu
BR7100920U (pt) Kit-pipoqueira
BR9105539A (pt) Cover-matelasse hospitalar
ATA23591A (de) Muenzkassa
ATA235591A (de) Eluiergeraet

Legal Events

Date Code Title Description
MA Patent expired